Medsafe lets two psychiatrists prescribe pharmaceutical MDMA for PTSD

Medsafe published the decision on 4 September. Two New Zealand psychiatrists may now prescribe pharmaceutical-grade MDMA as part of a treatment plan for adults with post-traumatic stress disorder whose symptoms have not responded to standard care.

The regulator was careful about what it did not do. MDMA has not been approved as a medicine in New Zealand. Evidence on its use for PTSD is still coming in from overseas trials. Any other clinician who wants to prescribe it must file a separate application. Patients will not be handed capsules to take home. Doses stay inside a clinic, under the authorised psychiatrist, inside a protocol Medsafe has seen.

Patients must be 18 or older. They need a full clinical assessment before anyone considers a session. The psychiatrist has to show substantial expertise and set out, in writing, how the sessions will run. Informed consent is required. The product must be made to a pharmaceutical standard. That last point is the line the ministry draws between the clinic and the street version sold as ecstasy, which can contain the same active molecule and a long list of other things.

The path is the same one Medsafe used in 2025 when it let a psychiatrist prescribe medicinal psilocybin for treatment-resistant depression. New Zealand now has two clinicians approved for psilocybin and two for MDMA. The country is using Regulation 22 of the Misuse of Drugs Regulations rather than a new statute. That is slower and narrower than Australia’s class-based Authorised Prescriber scheme, which opened MDMA-assisted psychotherapy for PTSD in 2023.

Associate Health Minister David Seymour announced the change in political coverage. The ministry text itself is dry. It says Medsafe weighed the chance of a new option for a hard-to-treat group against the duty to keep patients from harm. It expects only a small number of people to qualify.

PTSD treatment in New Zealand still rests on trauma-focused psychotherapy and licensed medicines that do not work for everyone. Trial literature from Australia, North America and Europe has reported drops in symptom scores for some patients after a short course of MDMA-assisted sessions. Those studies are not large enough, or long enough, for a full marketing approval. That is why Medsafe kept the compound unapproved and named two people rather than a whole specialty.

Cost and access will decide who actually sits in a room. The ministry did not publish a public fee schedule. Earlier psilocybin work in New Zealand has been private and expensive. Nothing in Friday’s notice creates a funded national programme. District services will still treat most patients with the tools they already have.

The legal status of MDMA outside the clinic does not change. It remains a Class B controlled drug. Recreational possession and supply stay offences. The approval is a named-prescriber exception, not a rescheduling.

Watch the next applications. If more psychiatrists file and Medsafe says yes, the scheme grows by names, not by a single national green light. If adverse events appear, the regulator can pull an individual approval without touching the rest of the medicines list. That is the design. It is also the limit. Two clinics do not make a treatment system. They make a tightly watched experiment that Australia started three years earlier and that New Zealand has now chosen to copy at a smaller scale.